If you are interested in learning more about our research program, please call the
VOA Research Department
(757) 466-8683 (South side) or (757) 873-9833 (peninsula).

BREAST
GYN
GASTROINTESTINAL
GENITOURINARY
LEUKEMIA & LYMPHOMA
LUNG CANCER
MULTIPLE MYELOMA
SOLID TUMORS
SARCOMA
SUPPORTIVE CARE
TRANSPLANT/HIGH-DOSE

BREAST top

CALGB 40101: Adriamycin/Cytoxan versus Taxol as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes

NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients With Node-Negative Breast Cancer

NSABP B-38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node- Positive Breast Cancer: Docetaxel/Doxorubicin/ Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/ Cyclophosphamide Followed by DD Paclitaxel (DD AC —> P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC —> PG)

USO 04-111: Phase II Study of Doxil and Carboplatin, plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer

USO 05-116: Phase III, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Untreated Metastatic Breast Cancer

USO 04-070: Randomized Phase II Study of Weekly Irinotecan/Carboplatin with or without Erbitux in Patients with Metastatic Breast Cancer

USO 05-090: A Phase III, Multicenter, Randomized, Placebo- Controlled Trial Evaluating the Efficacy and Safety Of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer

Duke 1144: A Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 6 mg/kg every Three Weeks in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer

GYN top

USO 05076: A Randomized, Parallel Group, Open-Label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) versus Pegylated Liposomal Doxorubicin (Doxil/Caelyx) in Taxane/Platinum Refractory/Resistant Patients with Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer

GOG 220: Pelvic Mass Study to Develop Serum Proteomic Profiles (Signatures) for Epithelial Ovarian Cancer Diagnosis and Prognosis

GOG 175: A Randomized Phase III Trial of Carboplatin and Paclitaxel every 21 Days x 3 Courses plus weekly low dose Paclitaxel every week vs. Carboplatin and Paclitaxel every 21 days for 3 courses and Observation in patients with Early Stage Ovarian Carcinoma

GOG 0212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax versus No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to primary Platinum/Taxane Chemotherapy

GOG 204: A Randomized Phase III study of Paclitaxel plus Cisplatin versus Vinorelbine plus Cisplatin versus Gemcitabine plus Cisplatin versus Topotecan plus Cisplatin in Stage IVB, recurrent or persistent carcinoma of the cervix

GOG 209: A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF Versus Carboplatin/Paclitaxel in patients with Stage III and IV or recurrent endometrial cancer

GOG 218: A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel plus concurrent Bevacizumab (NSC#704865, IND #7921) followed by placebo, versus carboplatin and Paclitaxel plus concurrent and extended Bevacizumab, in women with newly diagnosed, previously untreated, stage III (sub optimal) and all stage IV, epithelial ovarian or primary peritoneal cancer

GASTROINTESTINAL top

NSABP C-08: A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab For the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon

USO 05-009: A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects with Metastatic Colorectal Cancer

NSABP R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum

CALGB 80101: A Phase III Intergroup Trial of Adjuvant Chemoradiation after resection of Gastric or Gastroesophageal Adenocarcinoma

CALGB 80405: A Phase III trial of Ironotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the combination of Bevacizumab or Cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum.

CALGB 80603: A Phase II study of sunitinib malate (SU11248, NSC #736511, IND#74,019) in patients with previously treated pancreatic adenocarcinoma with measurable metastatic disease following progression on front-line gemcitabine based therapy.

GENITOURINARY top

USO 05-015: Phase II study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy

USO 05-100: A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

USO 05-113: A Phase 3, Randomized, Open-label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)

CALGB 90401: A Randomized Double-blind Placebo controlled phase III trial comparing Docetaxel and Prednisone with and without Bevacizumab in men with Hormone Refractory Prostate Cancer

Cell Genesys G0029: A Phase III randomized study of CG1940 and CG8711 vs. Docetaxel and Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer who are chemotherapy naïve

DENDREON 9902B: A Randomized, Double Blind, Placebo Phase III Trial of immunotherapy with autologous antigen presenting cells loaded with Provenge in men with Metastatic Androgen Independent Prostate Adenocarcinoma

USO 05-149: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer

USO 05-100: A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

USO 05-100: A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

BMS CA 183002: A multicenter, randomized double blind phase II/III study in the first line treatment of advanced transitional cell carcinoma (TCC) of the urothelium comparing vinflunine/gemcitabine to placebo/gemcitabine in patients who are ineligible to receive cisplatin-based therapy (VINCENT)

LEUKEMIA & LYMPHOMA top

USO 04-129: A Phase II Study of VELCADE in Patients with Relapsed or Refractory Indolent Lymphoma

USO 03-017: A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia

USO 05-023: A Phase I, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study Of Intravenously Administered CNF1010 (17-(Allylamino)-17-Demethoxygeldanamycin [17-AAG]) In Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL)

USO 04-109: A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care (BSC) for the Treatment of Myelodysplastic Syndromes (MDS)

USO 04-026: A Phase II study of Gemzar, Novantrone and Rituxan in Relapsed or Refractory mantle Cell Lymphoma

USO 06-069: An Open-Label, Multicenter, Phase II study of AT-101 in combination with Rituximab in patients with untreated, grade I-II follicular non-Hodgkin's Lymphoma

Zevalin Trial: A Phase III open label prospective two armed multicenter randomized group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (Ibritumomam Tiuxetan) study regimen versus observation in patients with diffuse large B-cell lymphoma who are in complete remission after first line CHOP-Rituximab (CHOP-R) therapy

LUNG CANCER top

USO 05-004: A Phase III, Randomized, Multi-Center Study of the Efficacy of Weekly Taxoprexin ® in Combination with Carboplatin versus Paclitaxel in Combination with Carboplatin as First Line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

USO 05-082: A Randomized, Open-Label Phase II Study of Pemetrexed (Alimta) plus Carboplatin with or without Enzastaurin Hydrochloride, or Docetaxel plus Carboplatin as First Line Treatment in Patients with Advanced Stage Non-Small Cell Lung Cancer

CALGB 79803: A phase III chemoprevention trial of Selenium supplementation in persons with resected Stage I Non-Small Cell Lung Cancer

USO 04-107: Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy

USO 05-088: A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed versus Pemetrexed and Placebo in Patients with Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Chemotherapy

USO 05-014: A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Docetaxel versus Docetaxel and Placebo in Patients with Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Chemotherapy

USO 05-119: A Randomized Phase 2 Trial Comparing Amrubicin versus Topotecan as Second-Line Treatment in Patients with Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy

USO 05-121: A Phase II, randomized, open-label trial of biweekly Pemetrexed plus Gemcitabine vs. Pemetrexed or Pemetrexed plus Carboplatin in relapsed non-small cell lung cancer (NSCLC) after neoadjuvant or adjuvant chemotherapy

USO 06 018: A Phase III, double-blind, placebo-controlled study of maintenance Pemetrexed plus best supportive care versus best supportive care immediately following induction treatment for advanced non-small cell lung cancer

USO 05 111: A Phase II trial of single-agent Amrubicin in patients with extensive disease small cell lung cancer that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy

MULTIPLE MYELOMA top

USO 04-127: A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide plus Dexamethasone (Thal-Dex) versus DOXIL plus Thalidomide plus Dexamethasone (DOXIL-Thal-Dex) in Subjects with Newly Diagnosed Multiple Myeloma

SOLID TUMORS top

USO 05-095: A Phase I Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects with Non-Hodgkin's Lymphoma or Solid Tumors

USO 06 65: A Phase I, multicenter, dose-escalation study to investigate the safety and tolerability of ADH-1 in combination with 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in subjects with N-cadherin positive, advanced solid tumors

USO 06-094: A Phase I trial of intravenous Onconase® administered twice weekly in subjects with advanced solid tumors (protocol P30-121)

SARCOMA top

MC 05-33: A Phase III trial of Perifosine in patients with Sarcomas

SUPPORTIVE CARE top

CALGB 90201: A Randomized Double Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone

Duke 2739-01-5: A Randomized Phase II study of Gabapentin or Glutamine to prevent the neuropathic pain and myalgias associated with weekly Paclitaxel administration in Metastatic Breast and Lung Cancer patients

TRANSPLANT/HIGH-DOSE top

USO 04-099: A Randomized Phase II Trial of Outpatient Immunotherapy with Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy with Autologous PBSC Rescue

USO 02-057: A Randomized Phase II Trial of Neulasta (Pegfilgrastim) versus Neupogen (Filgrastim) to Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant for Patients with Non-Hodgkin's Lymphoma

USO 03-047: A Phase II Open-label Trial of Velcade in Velcade-naïve Patients with Multiple Myeloma who have undergone High-dose Melphalan Therapy followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Duke 97147: Intensive Induction Therapy followed by Early High Dose Chemotherapy and Bone Marrow Transplantation for Mantle Cell Lymphoma